Abstract
This prospective, single-arm, open label study demonstrates that a single dexamethasone intravitreal implant administered immediately after cataract surgery in Type 2 diabetic patients and at least mild nonproliferative diabetic retinopathy prevents the occurrence of postsurgical macular edema over the ensuing 3-month treatment period.